Eisai Inc. (Eisai) is a health care company, engaged in discovering, developing and marketing pharmaceutical products in the US. It is a subsidiary of Eisai Co., Ltd. The company's current products include Aricept for AlzheimerÃƒÂ¢Ã¢â€šÂ¬Ã¢â€žÂ¢s treatment, Aciphex for acid reflux, anticoagulant Fragmin, and anti-convulsant Zonegran. It focuses on research activities in therapeutic areas such as neurology, gastrointestinal disorders, oncology and acute care. It has successfully completed the acquisition of the bio pharmaceutical company, AkaRx, Inc. Recently, Eisai has filed regulatory applications to agencies in Japan, US and the EU, for approval of Eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic breast cancer. Eisai is headquartered in New Jersey, the US.